Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | CCR3 | P51677 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BMP1 | P13497 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5723844 | 0.88 | DPP8 (0.41) | DPP8DPP9GAARAB9AALDH1A1 | |
| SCHEMBL5723919 | 0.88 | DPP8 (0.47) | DPP8DPP9GAACCR3RAB9A | |
| SCHEMBL5723825 | 0.87 | DPP8 (0.38) | DPP8DPP9GAACCR3RAB9A | |
| SCHEMBL5723944 | 0.87 | DPP8 (0.42) | DPP8DPP9GAAALDH1A1MAPT | |
| SCHEMBL5723894 | 0.86 | DPP8 (0.41) | DPP8DPP9GAACCR3RAB9A | |
| SCHEMBL5723860 | 0.86 | RAB9A (0.47) | DPP8DPP9GAACCR3RAB9A | |
| SCHEMBL5723837 | 0.86 | CHRM4 (0.37) | DPP8DPP9GAACCR3RAB9A | |
| SCHEMBL5723938 | 0.85 | DPP8 (0.43) | DPP8DPP9GAACCR3RAB9A | |
| SCHEMBL5723645 | 0.85 | DPP8 (0.39) | DPP8DPP9GAACCR3RAB9A | |
| SCHEMBL5723807 | 0.84 | ENPP2 (0.42) | DPP8DPP9ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141564-B2 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-11-28 | — | — | US | disclosed |
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | DPP8 1397/4885DPP9 703/4885GAA 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.